Trials / Completed
CompletedNCT02741544
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 578 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To understand the safety and efficacy of Revlimid® 2.5mg and 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1. Planned registration period This period started on the date of initial marketing of Revlimid and will end at the time when the planned number of patients to be enrolled is reached. 2. Planned surveillance period This period started on the date of initial marketing of Revlimid and will end on the day when the approval condition related to all-case surveillance is terminated.
Conditions
Timeline
- Start date
- 2016-03-03
- Primary completion
- 2020-08-20
- Completion
- 2020-08-20
- First posted
- 2016-04-18
- Last updated
- 2022-06-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02741544. Inclusion in this directory is not an endorsement.